JCR Pharmaceuticals ads

On our 50th anniversary, we are reflecting on where we started – six people in a tiny lab. It’s amazing to see how far we’ve come and the science we created in that time, including the development of our innovative platform technologies, J-Brain Cargo® and JUST-AAV gene therapy. Looking ahead, we aim to continue producing unexpected breakthroughs. We hope you'll follow our journey as we look ahead to the next 50 years, continuing to focus on patients around the world living with rare and genetic diseases. Hear from some of our senior leadership team about JCR, our mission, and what we've accomplished over the last 50 years in the below video. Learn more about our proprietary platform technologies, J-Brain Cargo® and JUST-AAV gene therapy, here: https://lnkd.in/exdxCaDG. #JCRTurns50 #JUSTAAV #GeneTherapy #Innovation #JCRPharma

At JCR Pharmaceuticals, we combine deep scientific expertise with a flexible, partnership-driven model to accelerate drug development in rare and neurological diseases. After 50 years, we have developed a blueprint for global impact. As we look ahead, we will continue to build strategic partnerships with companies and organizations that share our mission to deliver therapies to people around the world living with rare and genetic diseases. Learn more about our innovative technology platforms, J-Brain Cargo® and JUST-AAV gene therapy, and opportunities to partner with us: https://bit.ly/48khAbo. #FierceBiotech #JCRTurns50 #JUSTAAV #GeneTherapy #Innovation #JCRPharma

How do you treat what therapies can’t reach? Our proprietary platform technology, J-Brain Cargo®, crosses through the blood-brain barrier (#BBB), offering new hope for central nervous system (CNS)-targeted treatments. Versatile, scalable, and designed for impact—it's redefining what's possible for rare disease and neurodegenerative research & development. Anne Bechet, our Senior Executive Officer, Executive Director, Development Division, shares her perspective on our how J-Brain Cargo® can address the neurological signs and symptoms associated with lysosomal storage disorders and other CNS-related diseases in the below video. Learn more about J-Brain Cargo® and our other innovative, gene therapy platform technology, JUST-AAV, here: https://lnkd.in/exdxCaDG. #DrugDevelopment #BloodBrainBarrier #RareDisease #Neurodegeneration #JCRTurns50 #JCRPharma

From a domestic pioneer to a global innovator, JCR Pharmaceuticals has spent 50 years advancing therapies for patients worldwide. Today, we’re looking ahead to develop treatments for those with no alternatives, and partnering to go further, together. Explore our commitment to rare disease innovation and central nervous system breakthroughs like J-Brain Cargo® and JUST-AAV: https://lnkd.in/eUuvsqRF. #DrugDevelopment #PurposeDriven #RareDisease #JCRTurns50 #JCRPharma

Today, JCR Pharmaceuticals presented new non-clinical data demonstrating the ability of its proprietary JUST-AAV capsid engineering platform to achieve efficient delivery of adeno-associated virus (AAV) gene therapy to the central nervous system (CNS) and muscle while reducing liver exposure. The data, presented during an oral session at the European Society of Gene and Cell Therapy 32nd Annual Congress, showcase the platform’s potential to overcome longstanding challenges in treating CNS and muscle disorders. JCR researchers reported that the JUST-AAV platform enables the precise and efficient delivery of an AAV gene therapy across the blood-brain barrier (BBB) and into the CNS, as well as to the muscle in mice and monkeys. Read the full news release here: https://bit.ly/4h2YSI4. #RareDisease #LysosomalStorageDisorders #JCRPharma #BloodBrainBarrier #Neurodegeneration #CNS #GeneTherapy #ESGCT2025

We are attending the European Society of Gene and Cell Therapy 32nd Annual Meeting next week in Seville, Spain! Shunsuke Iizuka, Ph.D., JCR Pharmaceuticals, will present non-clinical data in an oral session on Tuesday, October 7 between 5-7:30pm CEST. The title of the presentation is "Generation of a novel capsid engineering platform enhances CNS and muscle tropism of AAV vectors while reducing tropism to the liver." We look forward to sharing updates from our JUST-AAV gene therapy research programs. Read the full news release here: https://bit.ly/3IJDWcg. See you at #ESGCT2025 if you are planning to attend! #RareDisease #GeneTherapy #ESGCT2025 #Innovation #JCRPharma